These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25330770)

  • 21. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
    Karakas D; Ozpolat B
    J Mol Med (Berl); 2020 Jun; 98(6):775-787. PubMed ID: 32377852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.
    Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
    Cancer Biother Radiopharm; 2012 May; 27(4):227-33. PubMed ID: 22489661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women.
    Khan F; Esnakula A; Ricks-Santi LJ; Zafar R; Kanaan Y; Naab T
    Pathol Res Pract; 2018 May; 214(5):673-678. PubMed ID: 29653745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
    Reed DE; Shokat KM
    Mol Cancer Res; 2017 Jun; 15(6):765-775. PubMed ID: 28196852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.
    Chiche A; Moumen M; Romagnoli M; Petit V; Lasla H; Jézéquel P; de la Grange P; Jonkers J; Deugnier MA; Glukhova MA; Faraldo MM
    Oncogene; 2017 Apr; 36(17):2355-2365. PubMed ID: 27775073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.
    Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE
    Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
    Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
    Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
    [No Abstract]   [Full Text] [Related]  

  • 29. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.
    Jiang Z; Deng T; Jones R; Li H; Herschkowitz JI; Liu JC; Weigman VJ; Tsao MS; Lane TF; Perou CM; Zacksenhaus E
    J Clin Invest; 2010 Sep; 120(9):3296-309. PubMed ID: 20679727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circular RNA circ-ZEB1 acts as an oncogene in triple negative breast cancer via sponging miR-448.
    Pei X; Zhang Y; Wang X; Xue B; Sun M; Li H
    Int J Biochem Cell Biol; 2020 Sep; 126():105798. PubMed ID: 32629026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
    Zecchin D; Moore C; Michailidis F; Horswell S; Rana S; Howell M; Downward J
    EMBO Mol Med; 2020 Aug; 12(8):e11987. PubMed ID: 32672423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
    Dragoj M; Bankovic J; Sereti E; Stojanov SJ; Dimas K; Pesic M; Stankovic T
    Invest New Drugs; 2017 Dec; 35(6):718-732. PubMed ID: 28733702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling.
    Chiche A; Di-Cicco A; Sesma-Sanz L; Bresson L; de la Grange P; Glukhova MA; Faraldo MM; Deugnier MA
    Breast Cancer Res; 2019 Jan; 21(1):13. PubMed ID: 30683141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.
    Fink LS; Beatty A; Devarajan K; Peri S; Peterson JR
    Mol Cancer Ther; 2015 Jan; 14(1):298-306. PubMed ID: 25344583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple-Negative Breast Cancer.
    Zhong C; Zhu R; Jiang T; Tian S; Zhao X; Wan X; Jiang S; Chen Z; Gong R; He L; Yang JM; Ye N; Cheng Y
    Adv Sci (Weinh); 2024 Feb; 11(5):e2305035. PubMed ID: 38084501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular stratification within triple-negative breast cancer subtypes.
    Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
    Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
    Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
    Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
    Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
    Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.
    Liu YY; Yao SN; Zhao Y; Yao ZH; Ma J; Xia QX; Fu K; Yang SJ
    Leuk Lymphoma; 2010 Sep; 51(9):1692-8. PubMed ID: 20807096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.